trial

Imaging Cannabinoid CB1 Receptors in Schizophrenia

NCTId NCT01063335
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Terminated
Enrollment 1 (actual)
Sponsored by National Institute of Mental Health (NIMH)
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
1 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2010-02-01
Primary completion
—
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
—

Sponsors

National Institute of Mental Health (NIMH)Lead Sponsor

Investigators

1
Robert C Smith, M.D., Ph.DPrincipal Investigator

Sites

1 total
Bethesda, United States

Facts & assertions

3 sourced
Enrollment
1
Phase
NA
Status
TERMINATED
relationships
The graph out of here
lead_sponsor
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Robert C Smith, M.D., Ph.D
person